Wickerhauser M, Williams C, Mercer J
Vox Sang. 1979;36(5):281-93. doi: 10.1111/j.1423-0410.1979.tb04436.x.
A large scale method for preparation of antithrombin III (AT III) concentrate from plasma or from Cohn fraction IV-1 (Fr. IV-1) has been described. It consists of the following steps: (a) partial purification by precipitation of impurities with 20% polyethylene glycol (PEG) 4000; (b) isolation of AT III from the PEG supernatant by batch adsorption and elution on heparin-Sepharose at a ratio corresponding to 45 vol of plasma or 80 vol of 10% Fr. IV-1 solution to 1 vol of gel; (c) concentration and desalting of the eluted AT III on a Pellicon ultrafiltration system; (d) pasteurization of AT III concentrate by heating for 10 h at 60 degrees C in the presence of 0.5 M sodium citrate at pH 7.5; (e) removal of excess citrate by gel filtration on Sephadex G-50; and (f) sterile filtration, filling and lyophilization. The recovery by activity was 32% from a 113-liter plasma batch and 16% from a 42-kg Fr. IV-1 batch. Both AT III concentrates, derived either from plasma or from Fr. IV-1, had similar specific activity and electrophoretic purity, were nonpyrogenic and met all other FDA requirements for biologic products. Pasteurization induced changes in disc gel and isotachophoretic patterns of AT III preparations.
已描述了一种从血浆或科恩IV-1组分(Fr.IV-1)制备抗凝血酶III(AT III)浓缩物的大规模方法。它包括以下步骤:(a)用20%聚乙二醇(PEG)4000沉淀杂质进行部分纯化;(b)通过在肝素-琼脂糖上进行批量吸附和洗脱,从PEG上清液中分离AT III,血浆与凝胶的比例为45体积血浆或80体积10%Fr.IV-1溶液比1体积凝胶;(c)在Pellicon超滤系统上对洗脱的AT III进行浓缩和脱盐;(d)在0.5M柠檬酸钠(pH 7.5)存在下于60℃加热10小时对AT III浓缩物进行巴氏消毒;(e)通过在Sephadex G-50上进行凝胶过滤去除过量的柠檬酸盐;以及(f)无菌过滤、灌装和冻干。从113升血浆批次中活性回收率为32%,从42千克Fr.IV-1批次中活性回收率为16%。源自血浆或Fr.IV-1的两种AT III浓缩物具有相似的比活性和电泳纯度,无热原性,并且符合FDA对生物制品的所有其他要求。巴氏消毒导致AT III制剂的圆盘凝胶和等速电泳图谱发生变化。